



Pfizer
Innovative
Health



Cowen and Company Health Care Conference

Pfizer Oncology

Andy Schmeltz
Global President, Pfizer Oncology

March 14, 2018

Forward Looking Statements

This presentation includes forward-looking statements about, among other things, Pfizer's oncology in-line products and product candidates, including anticipated regulatory submissions, approvals, performance and potential benefits of Pfizer's oncology products and product candidates, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.


Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors that May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.



Pfizer Oncology Growth Trajectory

Growing in-line portfolio fueled by IBRANCE & XTANDI with potential for multiple launches on the horizon



	2010	2011	2012	2013	2014	2015	2016	2017	2018E*	2019E*	2020E*
# Approved Medicines*	2	3	5	5	5	6	7	10	12	14	14
# Approved Indications*	3	5	7	8	8	9	11	17	20	21	28

Curve is for illustrative purposes only

*numbers for 2018-2020 reflect potential approvals and indications that are expected and may not materialize






A Rich Oncology Pipeline

as of February, 2018

Angiogenesis	Cell Cycle & Metabolism	Immunotherapy
Cell Signal Transduction / Oncogenic Driver	Antibody Drug Conjugate	Therapeutic Vaccine



¹ Registration/Approvals: Only includes major regions (US, EU, JPN, CHN).

* Additional clinical studies being conducted in other tumor types/segments and earlier phases.



Focused to Realize Our Vision

To Be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer

Key Focus Areas

IBRANCE & XTANDI*

- Partner with key stakeholders in the breast and prostate cancer communities
- Generate evidence for broader and optimal use

Pipeline

- Talazoparib: PARP inhibitor
- Avelumab: backbone PD-L1 therapy
- Identify and interrogate rational combinations with IO and non-IO mechanisms



**PATIENTS
FIRST**
Think Big, Take Pride, No Excuses

- Innovative and meaningful patient engagement
- Advancing access via outcomes and real world evidence
- Redefining life with cancer

Pfizer Oncology together™
Patient Support. Financial Assistance. Together.

*Pfizer and Astellas jointly commercialize XTANDI in the United States



Pfizer
Innovative
Health



Pfizer
Oncology

Q&A

Andy Schmeltz
Global President, Pfizer Oncology